Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$24.84 +1.4%	$23.61	$14.75 ▼ $26.16	$2.99B	0.7	1.11 million shs	937,199 shs
MRUS Merus	$50.80 -7.9%	$42.93	$33.19 ▼ $61.28	$3.82B	0.94	741,469 shs	2.72 million shs
XENE Xenon Pharmaceuticals	$29.46 -1.0%	$33.41	$26.74 ▼ $46.00	$2.26B	1.21	525,847 shs	1.06 million shs
XNCR Xencor	$7.75 +2.4%	$9.45	$7.16 ▼ $27.24	$551.58M	0.99	657,047 shs	1.49 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	+1.43%	+0.65%	+5.93%	+20.70%	+56.52%
MRUS Merus	-7.87%	+15.43%	+16.59%	+11.57%	-15.32%
XENE Xenon Pharmaceuticals	-0.97%	-6.27%	-21.69%	-24.65%	-23.22%
XNCR Xencor	+2.38%	-4.79%	-26.26%	-46.11%	-67.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.7222 of 5 stars	3.6	1.0	3.9	4.3	3.3	2.5
MRUS Merus	3.05 of 5 stars	4.6	3.0	0.0	2.7	1.7	0.0
XENE Xenon Pharmaceuticals	3.4887 of 5 stars	4.5	4.0	0.0	3.6	1.7	0.0
XNCR Xencor	3.9356 of 5 stars	3.4	1.0	3.9	3.7	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.13	Buy	$32.29	29.97% Upside
MRUS Merus	3.13	Buy	$86.00	69.29% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	86.08% Upside
XNCR Xencor	2.89	Moderate Buy	$29.50	280.65% Upside

Current Analyst Ratings Breakdown

Latest XNCR, MRUS, CPRX, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
5/7/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$534.65M	5.67	$2.32 per share	10.72	$3.30 per share	7.53
MRUS Merus	$54.73M	64.24	N/A	N/A	$6.17 per share	8.23
XENE Xenon Pharmaceuticals	$7.50M	301.41	N/A	N/A	$14.18 per share	2.08
XNCR Xencor	$127.23M	4.34	N/A	N/A	$10.99 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$71.41M	$1.57	21.05	11.66	3.31	31.01%	40.79%	34.87%	8/6/2025 (Estimated)
MRUS Merus	-$154.94M	-$4.08	N/A	N/A	N/A	-680.61%	-38.89%	-31.16%	7/30/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.23	N/A	N/A	N/A	N/A	-24.69%	-23.68%	8/14/2025 (Estimated)
XNCR Xencor	-$126.09M	-$3.06	N/A	N/A	N/A	-232.77%	-30.92%	-21.74%	8/4/2025 (Estimated)

Latest XNCR, MRUS, CPRX, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	5.11	4.92
MRUS Merus	N/A	8.32	8.32
XENE Xenon Pharmaceuticals	N/A	22.21	22.21
XNCR Xencor	0.01	6.23	6.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
MRUS Merus	96.14%
XENE Xenon Pharmaceuticals	95.45%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
MRUS Merus	4.57%
XENE Xenon Pharmaceuticals	5.52%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	121.98 million	106.15 million	Optionable
MRUS Merus	37	69.21 million	65.34 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.03 million	Optionable
XNCR Xencor	280	71.17 million	66.32 million	Optionable

XNCR, MRUS, CPRX, and XENE Headlines

Recent News About These Companies

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Two Sigma Investments LP

May 27 at 4:23 AM | marketbeat.com

Nuveen Asset Management LLC Purchases 685,557 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 26 at 3:54 AM | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC

May 26 at 3:12 AM | marketbeat.com

Two Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 25 at 4:33 AM | marketbeat.com

Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

May 25 at 3:18 AM | marketbeat.com

Xencor (NASDAQ:XNCR) vs. Dermata Therapeutics (NASDAQ:DRMA) Financial Comparison

May 19, 2025 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by RTW Investments LP

May 18, 2025 | marketbeat.com

Point72 Asset Management L.P. Sells 943,148 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 18, 2025 | marketbeat.com

Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)

May 17, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by Brokerages

May 16, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)

May 15, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings

May 13, 2025 | marketbeat.com

Wedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)

May 13, 2025 | marketbeat.com

Research Analysts Set Expectations for Xencor Q2 Earnings

May 13, 2025 | marketbeat.com

Deep Track Capital LP Has $11.49 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

May 9, 2025 | marketbeat.com

Braidwell LP Buys 149,083 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 8, 2025 | marketbeat.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor (NASDAQ:XNCR) Trading Down 6.1% - Should You Sell?

May 7, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR, MRUS, CPRX, and XENE Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$24.84 +0.35 (+1.43%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$24.76 -0.09 (-0.34%)

As of 05/27/2025 07:59 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Merus NASDAQ:MRUS

$50.80 -4.34 (-7.87%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$51.20 +0.40 (+0.79%)

As of 05/27/2025 07:56 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Xenon Pharmaceuticals NASDAQ:XENE

$29.46 -0.29 (-0.97%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$29.92 +0.46 (+1.56%)

As of 05/27/2025 07:43 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xencor NASDAQ:XNCR

$7.75 +0.18 (+2.38%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$7.76 +0.00 (+0.06%)

As of 05/27/2025 04:28 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time